Hybio Pharmaceutical Co Ltd
300199
Company Profile
Business description
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
Contact
4th Floor, Office Building, Hanyu Biomedical Park
Middle District, High-tech Industrial Park
Nanshan District
Guangdong Province
Shenzhen518057
CHNT: +86 75526588000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,035
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks
Tesla: Board announces new pay package for CEO Elon Musk
A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,028.80 | 106.80 | 1.20% |
| CAC 40 | 7,649.95 | 17.94 | 0.24% |
| DAX 40 | 23,928.33 | 170.64 | 0.72% |
| Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
| FTSE 100 | 9,161.94 | 33.64 | 0.37% |
| HKSE | 24,902.53 | 169.08 | 0.68% |
| NASDAQ | 21,053.58 | 403.45 | 1.95% |
| Nikkei 225 | 40,549.54 | 258.84 | 0.64% |
| NZX 50 Index | 12,877.04 | 193.00 | 1.52% |
| S&P 500 | 6,329.94 | 91.93 | 1.47% |
| S&P/ASX 200 | 8,770.40 | 106.70 | 1.23% |
| SSE Composite Index | 3,617.60 | 34.29 | 0.96% |